Entrectinib As First-Line Vs. Second-Line Therapy in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: a Cost-Effectiveness Analysis
TRANSLATIONAL LUNG CANCER RESEARCH（2024）
Key words
Entrectinib,cost-effectiveness,non-small cell lung cancer (NSCLC),ROS1,Markov model
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined